Jennifer A. Woyach, MD, provides an overview on some of the updated safety and efficacy data observed with pirtobrutinib in the phase 1/2 BRUIN study.
Jennifer A. Woyach, MD, hematologist-oncologist, professor, the Division of Hematology, the Ohio State University Comprehensive Cancer Center– James, provides an overview on some of the updated safety and efficacy data observed with pirtobrutinib (Jaypirca) in the phase 1/2 BRUIN study (NCT03740529).
Heavily pretreated patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) were enrolled in the study and given pirtobrutinib after previous treatment with a covalent Bruton tyrosine kinase (BTK) inhibitor.
In this video, Woyach discusses the response rates and trends observed across patient subgroups, and provides an overview on some of the adverse events that have been observed with pirtobrutinib treatment in this space.
Transcription:
0:10 | We looked further at response rate in some different patient subgroups between the BCL2-naive and the BCL2-exposed subgroup. There were not a lot of surprising trends there. There was a trend toward a lower response rate in patients with [phospholipase C gamma1 (PLCG1)] mutations. That is the protein immediately downstream of BTK, and [one] would expect that a mutation there might lead to a lower response rate. Importantly, higher-risk characteristics, so things like TP53 alterations [or] IGHV-unmutated disease, did not seem to affect response rate.
0:40 | Pirtobrutinib has been exceptionally well-tolerated in clinical trials. Most of the toxicities are grades 1 and 2. The more common things we see are some kind of common toxicities. In general, people tend to sometimes have some gastrointestinal [adverse] effects. Bruising is pretty common, [and] neutropenia was fairly common among the cytopenia toxicities. When looking at adverse events of special interest, for things that we think about with BTK inhibitors like atrial fibrillation, hypertension, bleeding rates, all of those were very low. There was about a 4% rate of atrial fibrillation, but a 4% risk of higher-grade hypertension, and high-grade bleeding was about 2%.
Leslie Reviews Relevant Data for Treatment of Relapsed/Refractory CLL
May 8th 2024During a Case-Based Roundtable® event, Lori A. Leslie, MD, discussed Bruton tyrosine kinase inhibition options for a patient with relapsed/refractory chronic lymphocytic leukemia in the first article of a 2-part series.
Read More
Marks Explores Cardiac Toxicities and Dosing Concerns of BTK Inhibitors in CLL
April 26th 2024During a Case-Based Roundtable® event, Stanley M. Marks, MD, moderated a discussion on the impact of cardiac adverse events on patients who receive a Bruton tyrosine kinase inhibitor for chronic lymphocytic leukemia.
Read More
Considering the Durability of Zanubrutinib in Relapsed/Refractory CLL
April 11th 2024During a Case-Based Roundtable® event, Marc S. Hoffmann, MD, discussed his viewpoints on the use of Bruton tyrosine kinase inhibitors for patients with relapsed/refractory chronic lymphocytic leukemia and the efficacy behind zanubrutinib in the second article of a 2-part series.
Read More
Acalabrutinib/Obinutuzumab Shows Improved PFS in Treatment-Naive CLL
April 10th 2024In an interview with Targeted Oncology, Jeff Sharman, MD, discussed the results of the ELEVATE-TN trial of acalabrutinib with or without obinutuzumab at 74.5 months of follow-up among patients with chronic lymphocytic leukemia.
Read More